RDY Dr. Reddy's Laboratories Ltd. ADR Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
07:04
Jul 30
Jul 30
Bloomberg Markets
Dr. Reddy's sees strong Q3/Q4 recovery
After resolving semaglutide production scale-up issue by November, the company expects very healthy Q3 and Q4 earnings, supported by a weak rupee (costs in rupees, sales in dollars) and a strong product pipeline.
RDY
Dr. Reddy's Laboratories Ltd. ADR
Long
1ST
—
—
20:41
Feb 03
Feb 03
r/ValueInvesting
Dr. Reddy's among generic semaglutide launch winners
Author lists Dr. Reddy's among generic semaglutide makers that will launch in Brazil and India alongside Sandoz, Biocon, and Teva, and he discloses holding RDY. The thesis is that patent expirations for semaglutide open generic opportunities for these companies. No separate risk beyond the generic-space competition is stated.
RDY
Dr. Reddy's Laboratories Ltd. ADR
Long
1ST
—
—
About RDY Investor Commentary
Across the available history and selected sources, Buzzberg tracks RDY (Dr. Reddy's Laboratories Ltd. ADR) across 5 sources: 2 bullish vs 0 bearish calls from 5 authors. Historical directional balance: 33% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 6 total trade ideas tracked. Latest voices: Erez Israeli, u/TheAirNearMyFingers.